Health
STAT+: In Shanghai’s ‘Science City,’ China’s ascendant biotechs make their pitch to the world
Publication: STAT
Author: Jason Mast
Source published: 01/10/2026, 08:30:00 UTC
Briefing created: 02/10/2026, 02:20:20 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 01/10/2026, 22:22:24 UTC.
Briefings
In October 2026, four biotech executives from Shanghai's 'Science City' district presented at the Hilton ballroom, claiming China's drug development is faster, cheaper, and more efficient than the US. Zhui Chen, co-founder of Abbisko, highlighted a trial on a Merck KGaA drug completed in 11 months, prompting Merck to offer training opportunities. The event occurred in a glimmer-and-glass district, but specific attendee names, exact financial figures beyond the $6 billion valuation, and comparative performance metrics against the US remain unverified.
Key points
- Four biotech executives presented at the Hilton ballroom in Shanghai's Science City district in October 2026, claiming China's drug development is faster, cheaper, and more efficient than the US.
- Zhui Chen, co-founder of Abbisko, cited a trial on a Merck KGaA drug completed in 11 months, leading Merck to offer staff training opportunities.
Context and limitations
Specific attendee names, exact financial figures beyond the $6 billion valuation, and comparative performance metrics against the US remain unverified. The article does not confirm the trial's outcome or the extent of Merck's training offer.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 02/10/2026, 02:20:20 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeidb3nbsg35u7v7pbmq5i6hyzn3g42txmidns2h7sohhvh5ocf6kvi